Leonard J. Sokolow - 14 Sep 2026 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Reporting relationship: Director
Issuer ticker: VVOS
Reported as of: 14 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Sep 2026, 20:20:23 UTC
Prior SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Bradford K. Amman as attorney-in-fact for Leonard J. Sokolow

Key filing fact

Leonard J. Sokolow filed Form 4 for Vivos Therapeutics, Inc. (VVOS) on 18 Sep 2026.

Key facts

This page summarizes Leonard J. Sokolow's Form 4 filing for Vivos Therapeutics, Inc. (VVOS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Sep 2026, 20:20.

Change

Previous filing in this sequence was filed on 14 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000923890 Primary reporting owner

SOKOLOW LEONARD J

Relationship: Director
Address: 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON
Signature: /s/ Bradford K. Amman as attorney-in-fact for Leonard J. Sokolow
Signature date: 18 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VVOS transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +12,000
Change %: +214%
Price: $0.000000^*
Shares after: 17,600
Date: 14 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $0.1800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date. Reflects expiry of 667 options on June 19, 2025 and 1,200 options on August 5, 2026, all of which expired unexercised.